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Application of the Euroimmun anti-SARS-CoV-2-S1-IgG ELISA 
antibody test to dried blood spots 
The qualitative Euroimmun anti-SARS-CoV-2-S1-IgG ELISA antibody test has been most commonly used 
in the analysis of serum samples since early 2020. In the population-based seroepidemiological study 
'CORONA-MONITORING bundesweit' (RKI-SOEP study) [1], however, it is used to analyse dried blood 
spots (DBS). A method study was therefore conducted comparing serum with dried blood, embedded 
in the 'CORONA-MONITORING lokal' study [2]. This method study comprised 276 individuals who had 
participated both in the baseline survey in May/June 2020 and in the follow-up survey of the study 
'CORONA-MONITORING lokal' in October 2020. The sample was made up of individuals who either had 
a positive or indeterminate IgG test result in serum measurements at the time of the baseline survey 
(n = 265) or had a negative test result but reported a positive PCR test before the baseline survey in 
the questionnaire (n = 11).  
Study execution and laboratory methods 
During the follow-up survey, the study team collected both a venous blood sample, which was pro-
cessed into serum, and a capillary blood sample, which was processed into dried blood. Both samples 
were tested for IgG antibodies using the anti-SARS-CoV-2-S1-IgG ELISA (trade name “Anti-SARS-CoV-2 
ELISA (IgG)“, Euroimmun AG, Lübeck, Germany, batch E200518BC). The results of this test are semi-
quantitative ratio values which were classified for serum samples using the manufacturer-supplied 
cutpoints (positive: ratio ≥ 1.1; indeterminate: 0.8 ≤ ratio < 1.1, negative: ratio < 0.8). 
Statistical analysis 
The aim of the analysis was to examine the test characteristics of the IgG test based on DBS compared 
to serum samples and, if appropriate, to derive a cutpoint adapted to dried blood so that the seroprev-
alence based on dried blood is comparable to a seroprevalence based on serum samples. The catego-
rization used was 'positive' versus 'non-positive' (negative or indeterminate). Results of the serum 
measurement using the manufacturer-supplied cutpoints were regarded as the gold standard for the 
present analysis. 
On the one hand, the adapted cutpoint was determined by minimizing the misclassification rate. To 
this purpose, cutpoints in the range 0.7–1.1 were used to classify the dried blood ratio values. This 
range was chosen since first analyses showed that dried blood spot samples yielded somewhat lower 
ratio values than serum samples. For each cutpoint, the proportion of misclassified DBS test results in 
comparison to serum results was determined, i.e. the proportion of all dried blood samples that were 
classified differently from the corresponding serum sample. Confidence intervals for the proportion of 
misclassified DBS test results were calculated using the Wilson score method [3,4].  
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On the other hand, a correction formula was estimated to predict serum ratio values from DBS ratio 
values, and the cutpoint was converted using this formula. The correction formula was estimated via 
piecewise linear regression, with the ranges for the piecewise regression defined by examining residual 
plots. 
Results 
The measurements performed with dried blood (mean value 1.52; range 0.09–6.97) yielded slightly 
lower ratio values compared to the results from serum (mean value 1.68; range 0.11-6.72). Half of the 
serum samples collected in the follow-up survey were IgG positive (Table 1).1 Overall, the proportion 
of DBS samples misclassified was 5.1% compared to the corresponding serum sample, applying the 
manufacturer-supplied cutpoint to the DBS samples (14 of 276 dried blood samples were misclassified, 
95% CI: 3.0–8.3%) (see Table 1). All misclassifications were false negative categorizations (10.1% of 138 
positives in serum were categorized as negative in the DBS sample, 95% CI: 6.1–16.3%). 
Result of serum sample Result of dried blood spot sample 




Positive (≥ 1.1) 124 (89.9%)   14 (10.1%) 138 
Non-positive (< 1.1)     0 (0%) 138 (100%) 138 
Total 124 152 276 
Table 1: Categorized IgG measurement in serum vs. categorized IgG measurement in dried blood spot 
using the manufacturer-supplied cutpoint (number, row percentage) 
The minimum misclassification over all cutpoints tested was 2.9% (8 of 276 samples misclassified, 95% 
CI: 1.5–5.6%). It was reached with a cutpoint of 0.94 and 0.95, respectively (see Table 2; the categori-
zations for these two cutpoints were identical). With this cutpoint, false positive and false negative 
misclassifications occurred with equal frequency. 
1 Differences to the baseline IgG categorization may be explained by two factors: (1) waning of antibodies be-
tween baseline and follow-up; (2) use of a different test batch. 
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Result of serum sample Result of dried blood spot sample 




Positive (≥ 1.1) 134 (97.1%)     4 (2.9%) 138 
Non-positive (< 1.1)     4 (2.9%) 134 (97.1%) 138 
Total 138 138 276 
Table 2: Categorized IgG measurement in serum vs. categorized IgG measurement in dried blood spot 
using the cutpoint that minimizes the overall misclassification rate (number, row percentage) 
As another way to establish a cutpoint, a correction formula was derived to convert the DBS values 
into serum values. This resulted in a good model fit when using piecewise linear regression: 
(1) For DBS values < 0.19 (n = 8):
predicted serum ratio value = DBS value 
(2) For DBS values from 0.19 to 2.2 (relevant range for the categorization into positive/negative),
the following applies (n=201):
predicted serum ratio value = 0.074 + 1.093 × DBS ratio value 
The explained variance (R²) in this range is 95.5%. The intercept (0.074) has a standard error 
of 0.0169, and the slope parameter (1.093) has a standard error of 0.017. 
(3) For DBS values > 2.2 the following applies (n=67):
predicted serum ratio value = 0.166 + 1.013 × DBS ratio value 
The explained variance (R²) for these high DBS values is 92.1%. The intercept (0.166) has a 
standard error of 0.015 and is therefore not significantly different from zero. The slope param-
eter (1.013) has a standard error of 0.037 and is not significantly different from 1. 
Figure 1 (left panel) shows the data points together with the estimated regression line. The right panel 
of the figure examines the agreement between measured serum ratio values and the serum ratio val-
ues predicted from the regression on DBS ratio values, using a Bland-Altman plot [5]. For this plot, the 
difference between the measured value and the predicted value is plotted against the mean of the 
two values. The plot indicates a uniform distribution of differences around zero throughout the range 
of values with only a small number of outliers, indicating a good model fit.  
According to the correction formula (2), a DBS ratio value of 0.94 corresponds to a serum ratio value 
of 1.1 (by inverting the above regression equation: (1.1 − 0.074)/1.093 = 0.939). Thus, this method 
yields an adjusted cutpoint of 0.94 for dried blood spot samples. 
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Figure 1: Left panel: Data points and piecewise regression line for the regression of serum IgG ratio 
values on DBS IgG ratio values. Right panel: Bland-Altman plot of the difference between the measured 
serum IgG ratio value and the value predicted by the regression model against the mean of the two 
values. The lines show the limits of agreement (red, dashed line: ± 2 standard deviations; green, dotted 
line: ± 3 standard deviations).  
Implementation in the analysis of the seroprevalence study 
Both using the correction formula and by minimizing the misclassification rate, 0.94 is obtained as the 
adapted cutpoint for classifying dried blood spot samples as IgG positive. This cutpoint was therefore 
used in the evaluation of the RKI-SOEP seroprevalence study [1] to classify the ratio values of the Eu-
roimmun IgG antibody test in dried blood spot samples. 
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